digitizing Proteomics To Transform Human HeAlth
The functional drivers of biology,
Proteins are the final frontier to understanding life itself.
Prisma Bio, a breakthrough protein sequencing tools company, is digitizing the proteome to unveil novel drug targets, disease mechanisms, and biomarkers to improve patient outcomes.
OUR Technology
The Digital Proteome: Unveiling the Final Frontier of Biomedical Research
Prisma is advancing breakthrough protein sequencing technologies to unveil the true functional drivers of biology and transform human health.
Imagine a world where we can resolve every protein within a sample, revealing its identity and quantity with stunning resolution.
This is the future Prisma is building with unbiased, single-molecule protein sequencing, a revolutionary approach that analyzes proteins for hypothesis free discovery.
This video dives into Prisma's elegant protein sequencing technology. Our patented, Universal Recognizer is a single, small molecule dye that binds directly to the N-terminus of proteins and produces a distinct optical fingerprint for each amino acid and post-translational modification. Combined with our proprietary and cutting-edge, light-based sequencing approach, Prisma generates accurate amino acid sequences to enable unbiased, proteome-scale identification and quantification of proteins at the single-molecule level.
OUR Team
Amanda Cashin, PhD
Co-Founder & CEO
Anderson Chen, PhD
Co-Founder
Chief Imaging Tech Officer
Nathan Hendrick, PhD
Head of Chemistry
Zack McNealy, MBA
CFO
Drew Martin, PhD
Assay Development
Landon Kushimi
Data Science
Craig Hetherington, PhD Optical Engineering
OUR Advisors
Sammy Datwani, PhD Product Development
Andrew Emili, PhD
Co-Founder
Proteomics
Aaron Beeler, PhD
Co-Founder
Chemistry
Jake LaPorte, PhD
Co-Founder
Business
Bob Kain
Engineering
Xiaolin Nan, PhD
OHSU
Mark Crovella, PhD
Boston University
OUR investors
Carlo Rizzuto, PhD
Alex Mayweg, PhD
Follow us on LinkedIn for the latest
Contact us to learn more and explore how we might work together to tackle the final frontier of biology